Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco
withdrawal symptoms and increases long term cessation rates when combined with transdermal
nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized,
parallel group trial in which smokers aged 18-70 will be subject to the combination of oral
and patch treatments.
Phase:
Phase 2
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development